Rigel Pharmaceuticals Bolsa (NASDAQ: RIGL)

Últimas noticias sobre Rigel Pharmaceuticals (NASDAQ:RIGL) Bolsa

Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals Inc

WIIM

RIGL

Rigel Pharmaceuticals shares are trading lower after B. Riley Securities cut its price target on the stock from $27 to $20.

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $15 to $25.

News

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $25

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and lowers the price target from $27 to $20.

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Lowers Price Target to $20

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

<ul>
<li>R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients</li>
<li>RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial&nbsp;data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being&nbsp;presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.&nbsp;

Biotech

General

Rigel Pharmaceuticals Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated LR-MDS Patients

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $17 to $27.

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $27

Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies.

Rigel Announces R289 Granted Fast Track Designation By The FDA For Lower-Risk MDS

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $15 to $23.

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23

Rigel Pharmaceuticals shares are trading higher Citigroup maintained a Buy rating on the stock and raised its price target from $40 to $49.

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and raises the price target from $40 to $49.

Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $49

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVR

BNOX

FTRE

MRVI

NOTV

PRPH

RVNC

TIVC

12 Health Care Stocks Moving In Friday's Intraday Session

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.03 by 2233.33 percent. The company reported quarterly sales of $55.307 million which beat the analyst consensus estimate of $41.927 million by 31.91 percent. This is a 96.58 percent increase over sales of $28.134 million the same period last year.

Earnings

Earnings Beats

Rigel Pharmaceuticals Q3 2024 GAAP EPS $0.70 Beats $0.03 Estimate, Sales $55.307M Beat $41.927M Estimate

Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO&#xAE; (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). GAVRETO is for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The DHCP letter has been posted to the GAVRETO Healthcare Provider website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4286741-1&amp;h=3852763292&amp;u=https%3A%2F%2Fgavreto-hcp.com%2F&amp;a=www.gavreto-hcp.com">www.gavreto-hcp.com</a>.

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter For GAVRETO After Consultation With The U.S. FDA  For The Treatment Of Adult Patients With Metastatic Rearranged During Transfection

Optime Care Expands Partnership With Rigel Pharmaceuticals To Include Commercial Distribution Of TAVALISSE For Managing Chronic Immune Thrombocytopenia

Cantor Fitzgerald analyst Kristen Kluska reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and maintains $15 price target.

Cantor Fitzgerald Reiterates Neutral on Rigel Pharmaceuticals, Maintains $15 Price Target

Rigel Says First Patient Enrolled In Phase 1b/2 Triplet Therapy Trial Of Decitabine And Venetoclax In Combination With REZLIDHIA

Rigel Pharmaceuticals ( ($RIGL) ) has released its Q3 earnings. Here is a breakdown of the information Rigel Pharmaceuticals presented to its inves...

Rigel Pharmaceuticals Reports Strong Q3 2024 Results

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel (RIGL – Research Report) today and set a price target of $57.00. Joseph P...

Rigel's Robust Financial Performance and Strategic Partnerships Drive Buy Rating

Rigel stock rallies 36% after Q3 earnings beat

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Rige...

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

B. Riley raised the firm's price target on Rigel Pharmaceuticals (RIGL) to $27 from $17 and keeps a Neutral rating on the shares. The shares rallie...

Rigel Pharmaceuticals price target raised to $27 from $17 at B. Riley

Rigel Pharmaceuticals (RIGL) announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selecti...

Rigel Pharmaceuticals announces initial data from Phase 1b study of R289

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Rigel (RIGL – Research Report), with a price targ...

Cantor Fitzgerald Remains a Hold on Rigel (RIGL)

Cantor Fitzgerald raised the firm's price target on Rigel Pharmaceuticals (RIGL) to $25 from $15 and keeps a Neutral rating on the shares. Rigel an...

Comments

Rigel Pharmaceuticals

Noticias

Últimas noticias sobre Rigel Pharmaceuticals (NASDAQ:RIGL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL